ClinicalTrials.gg

Program

SYHX1901

A development code. Also written as “SYHX 1901 tablets”.

Its studies are mostly in Alopecia Areata · Psoriasis · Vitiligo · Drug-Related Side Effects and Adverse Reactions, led by CSPC Pharmaceutical Group.

Furthest: phase 3, since Apr 17, 20255 company-led studies, 3 open or runningNext primary completion: Apr 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group53 open or runningphase 3since Apr 17, 2025Apr 27, 2021Apr 28, 2027phase 3 · NCT06943950
  • Named in CSPC Pharmaceutical Group’s own pipeline as SYHX1901, phase 3, as of Aug 20, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2021First study: phase 1 study in Healthy SubjectsFirst studyNCT04880512 · 102 enrolled · China
  2. Mar 3, 2023Phase 2 study in Drug-Related Side Effects and Adverse ReactionsNCT05858047 · 93 enrolled · China
  3. Jul 2, 2024Phase 2 study in Non-segmental VitiligoNCT06511739 · 144 planned · China
  4. Aug 18, 2024Phase 2 study in Alopecia AreataNCT06562894 · 156 planned
  5. Apr 17, 2025Phase 3 study in Moderate to Severe Plaque PsoriasisNCT06943950 · 500 planned

Ahead

  1. Apr 28, 2027Primary completion: phase 3 study in Moderate to Severe Plaque PsoriasisNCT06943950
  2. May 31, 2027Primary completion: phase 2 study in Alopecia AreataNCT06562894

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06943950Moderate to Severe Plaque Psoriasis3Not yet recruitingApr 28, 2027500
NCT06562894Alopecia Areata2Not yet recruitingMay 31, 2027156
NCT06511739Non-segmental Vitiligo · China2RecruitingAug 1, 2025144
NCT05858047Drug-Related Side Effects and Adverse Reactions · China2CompletedFeb 21, 202493
NCT04880512Healthy Subjects · China1UNKNOWNAug 20, 2022102

How it is read

Names in the registry

  • “SYHX1901”, 4 entries
  • “SYHX 1901 tablets”, 1 entry

Codes read as this program: SYHX1901.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.